Long-acting cabotegravir plus rilpivirine noninferior to oral dolutegravir for HIV viral suppression
Long-acting Injections Show Potential for HIV Treatment Management
This Phase 3b randomized trial of 537 adults with virally suppressed HIV in East and Southern Africa found long-acting cabotegravir plus ril…
A new trial shows that long-acting injections may be as effective as daily pills for keeping HIV suppressed in patients with adherence chall…
Long-Acting Injections Beat Daily Pills for Teens With HIV
Long Acting Injection Shows Better Viral Suppression for HIV
In a randomized trial of 476 adolescents with HIV, long-acting cabotegravir-rilpivirine injections led to far fewer virological failures tha…
A new long acting injection may help adolescents with HIV maintain viral suppression more effectively than daily oral medication.
Healthcare workers in Sub-Saharan Africa show positive attitudes toward delivering both oral and injectable HIV PrEP
Healthcare Workers Show Positive Attitudes Toward HIV Prevention Medication
This narrative review examines the knowledge, perceptions, and readiness of healthcare workers in Sub-Saharan Africa regarding HIV pre-expos…
Healthcare workers in Sub-Saharan Africa show positive attitudes toward HIV prevention medication despite facing significant barriers like l…
Systematic review shows rapid diagnostic tests offer faster, cheaper HIV detection for LAI-PrEP users with low certainty evidence
Rapid tests find HIV just as well as lab tests but cost less and work faster
This systematic review and meta-analysis evaluated HIV detection strategies, including rapid diagnostic tests (RDTs), laboratory-based immun…
For people on long-acting HIV prevention, rapid tests match lab accuracy while cutting costs and speeding up treatment starts.
Cochrane review: injectable lenacapavir cuts HIV infections versus oral PrEP at 52 weeks
One Shot Saves You From HIV For Six Months
This Cochrane systematic review and meta-analysis of two randomised controlled trials (8660 participants) compared six-monthly subcutaneous …
A single shot under the skin protects against HIV for six months, solving the daily pill problem for millions at risk.